CBD has also been investigated for use in other forms of treatment-resistant epilepsy, usually in addition to conventional epilepsy medications. Results varied, but several trials showed CBD significantly reduced seizure frequency by almost 44% in most people. 3
In addition, more trials are needed to investigate its use for numerous other conditions, such as muscle-spasticity in multiple sclerosis, Alzheimer’s disease, substance-abuse treatment, and diabetes protection.
CBD can interact with other medications used for epilepsy and some serious side effects have been reported, notably, a decrease in liver function when given to people already taking valproate.
Unfortunately, few human trials investigating the use of CBD as a single agent to relieve pain exist, with most trials using a combination of CBD and THC to relieve pain. Notably, Health Canada has approved a combination medication that contains both THC and CBD in a 1:1 ratio for the relief of central nerve-related pain in multiple sclerosis, and cancer pain that is unresponsive to optimized opioid therapy.
More recent research points to THC being more effective at reducing nausea and vomiting than CBD.
According to an article in Molecules , scientists do not know precisely how CBD helps control seizures. One theory suggests that CBD influences a receptor involved in seizure activity called transient receptor potential vanilloid.
Researchers have investigated the pain-relieving effects of CBD. A small 2020 randomized, placebo-controlled trial investigated the use of topical CBD oil on people with peripheral neuropathy of the legs.
Keep reading to learn about some of the possible benefits of using CBD oil.
In this small study, participants with peripheral noncancer neuropathic pain received either 250 milligrams (mg) of CBD total dissolved in 3 oz of oil) or a placebo.
CBD is just one of many different molecules unique to the Cannabis plant. CBD oil generally contains low levels of the cannabinoid tetrahydrocannabinol (THC), which is the compound that produces the ‘high.’
Although the results of this small trial are positive, it involved just 29 participants, so researchers need to conduct more investigations to confirm the results.
However, the researchers do not know which of the two compounds had the most significant effect. Also, the follow-up period for this study was 15 weeks. Scientists must carry out further research to confirm whether long-term pain control is possible.
Epidiolex reduces seizures or stops them altogether. On June 25, the drug was approved to treat seizures associated with these forms of epilepsy. Researchers also suggest that CBD can treat complications that arise from epilepsy  , like neuronal injury, neurodegeneration, and psychiatric diseases.
Summary: Effective – Academic research proves that CBD can help reduce acne.
CBD is also a positive modulator for GABA, an inhibitory neurotransmitter that damps down the effects of excitatory chemicals like cortisol and norepinephrine, producing a calming effect. CBD supports the expression and production of GABA in the brain.
19. Reduce Symptoms of PTSD
JCJ Insight published a small study in 2017  , where researchers observed that CBD oil could help prevent blood-pressure fluctuations caused by stress. Recent research has also linked CBD with more benefits for the heart as well as the circulatory system, and the ability to lower high blood pressure.
CBD may work as an antioxidant and help reduce oxidative stress, a condition that occurs when the body has too many free radicals making it difficult for antioxidants to neutralize them. Hence, owing to the rising of toxicity in our environment, it’s a comparatively recent problem.
1. Establishment of a New Drug Code for Marihuana Extract (2016): the Federal Register (OFR)
2. John M. McPartland, William Hegman & Tengwen Long (2019): Cannabis in Asia: its center of origin and early cultivation, based on a synthesis of subfossil pollen and archaeobotanical studies. SpringerLink
3. Renée Johnson. (2019) Defining Hemp: A Fact Sheet. [online] The Federation of American Scientists (FAS)
4. FDA Regulation of Cannabis and Cannabis-Derived Products: Q&A. (2020). [online] U.S. Food and Drug Administration
5. Magdalena Cerdá, Melanie Wall, Katherine M Keyes, Sandro Galea, and Deborah Hasin (2012). Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse, and dependence. Journal of Drug Alcohol Depend. [online] 120(1-3), pp. 22–27.
6. Establishment of a New Drug Code for Marihuana Extract (2016). [online] The Office of the Federal Register (OFR)
7. Global Report Findings (2017). [online] GSK Global Pain Index 2017 Global Research Report GPI 2017 Global Report Findings 2 GPI 2017 Global Report Findings.
8. F M Leweke, D Piomelli, F Pahlisch, D Muhl, C W Gerth, C Hoyer, J Klosterkötter, M Hellmich, and D Koethe (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Journal of Transl Psychiatry, [online]
9. Ethan B Russo (2008) Cannabinoids in the management of difficult to treat pain. Journal of Ther Clin Risk Manag. [online] 4(1) Pages 245—259
10, 21 Barbara Costa, Gabriella Giagnoni, Chiara Franke, Anna Elisa Trovato, and Mariapia Colleoni (2004) Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the non-psychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Journal of Br J Pharmacol [online]
11. Pedro H.Gobira, Luciano R.Vilela, Bruno D.C.Gonçalves, Rebeca P.M.Santos, Antonio C.de Oliveira, Luciene B.Vieira, Daniele C.Aguiar, José A.Crippa, Fabricio A.Moreira (2015) Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. ScienceDirect [online]12. D.C. Hammell L.P. Zhang F. Ma S.M. Abshire S.L. McIlwrath A.L. Stinchcomb K.N. Westlund. (2015). Transdermal cannabidiol reduces inflammation and pain‐related behaviours in a rat model of arthritis. [online] British Journal of Pharmacology
13. Philpott, Holly T.; O’Brien, Melissa; McDougall, Jason J (2017). Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. [online] PAIN is the journal of the International Association for the Study of Pain
14, 15, 16, 17, 18. Ethan B. Russo (2016). Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes. Mary Ann Liebert, Inc.
19. National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Population Health and Public Health Practice and Evidence, A. (2017). Therapeutic Effects of Cannabis and Cannabinoids. [online] Nih.gov.
20. Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S.-R., Willenbring, D., Guan, Y., Pan, H.-L., Ren, K., Xu, Y. and Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. The Journal of Experimental Medicine, [online] 209(6), pp.1121–1134.
21. Costa, B., Giagnoni, G., Franke, C., Trovato, A.E., and Colleoni, M. (2004b). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. British Journal of Pharmacology, 143(2), pp.247–250.
22. Jadoon, K.A., Tan, G.D., and O’Sullivan, S.E. (2017a). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight, 2(12).
23. CBDAwarenessProject (2019). CBD for Cancer: Benefits & Treatment Guide. [online] CBD Awareness Project
24. Johnson, J.R., Burnell-Nugent, M., Lossignol, D., Ganae-Motan, E.D., Potts, R., and Fallon, M.T. (2010). Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC: CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain. Journal of Pain and Symptom Management, 39(2), pp.167–179.
25. Duran, M., Pérez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., Arriola, E., Rabanal, M., Pastor, A., Farré, M., Rams, N., Laporte, J.-R. and Capellà, D. (2010). Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. British Journal of Clinical Pharmacology, [online] 70(5), pp.656–663.
26. McAllister, S.D., Christian, R.T., Horowitz, M.P., Garcia, A. and Desprez, P.-Y. (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Molecular cancer therapeutics, [online] 6(11), pp.2921–7.
27. Shrivastava, A., Kuzontkoski, P.M., Groopman, J.E., and Prasad, A. (2011). Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Molecular cancer therapeutics, [online] 10(7), pp.1161–72.
28. Aviello, G., Romano, B., Borrelli, F., Capasso, R., Gallo, L., Piscitelli, F., Marzo, V.D., and Izzo, A.A. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. Journal of Molecular Medicine, [online] 90(8), pp.925–934.
29. National Toxicology Program (1996). NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Technical Report Series, [online] 446, pp.1–317.
30. Thomas, A.A., Wallner, L.P., Quinn, V.P., Slezak, J., Van Den Eeden, S.K., Chien, G.W. and Jacobsen, S.J. (2015). Association between cannabis use and the risk of bladder cancer: results from the California Men’s Health Study. Urology, [online] 85(2), pp.388–392.
31. Corroon, J., and Phillips, J.A. (2018). A Cross-Sectional Study of Cannabidiol Users. Cannabis and Cannabinoid Research, 3(1), pp.152–161.
32. thebossmagazine. (2019). CBD Oil Benefits for Skin: Everything You Need to Know. [online] BOSS Magazine.
33. Grinspoon, P. (2018). Cannabidiol (CBD) — what we know and what we don’t – Harvard Health Blog. [online] Harvard Health Blog.
34. askcbd (n.d.). CBD is a more powerful antioxidant than vitamins C and E. [online] Ask CBD.
35. Wikipedia Contributors (2019). History of medical cannabis. [online] Wikipedia.
36. Bayle, A. (2019). How to Use CBD Oil for Skin Cancer. [online] Hemppedia.
37. Leafly. (2020). What is Rick Simpson Oil? | Make & use RSO. [online]
38. Tan, J.K.L., and Bhate, K. (2015). A global perspective on the epidemiology of acne. The British journal of dermatology, [online] 172 Suppl 1, pp.3–12.
39, 40. Oláh, A., Tóth, B.I., Borbíró, I., Sugawara, K., Szöllõsi, A.G., Czifra, G., Pál, B., Ambrus, L
., Kloepper, J., Camera, E., Ludovici, M., Picardo, M., Voets, T., Zouboulis, C.C., Paus, R. and Bíró, T. (2014a). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. The Journal of Clinical Investigation, [online] 124(9), pp.3713–3724.
41. DrugAbuse.GOV (2019). Opioid Overdose Crisis. [online] Drugabuse.gov.
42. Russo, E.B. (2008). Cannabinoids in the management of difficult to treat pain. Therapeutics and Clinical Risk Management, [online] 4(1), pp.245–259.
43. Li, H., Kong, W., Chambers, C.R., Yu, D., Ganea, D., Tuma, R.F., and Ward, S.J. (2018). The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice. Cellular Immunology, 329, pp.1–9.
44, 45. Jadoon, K.A., Tan, G.D., and O’Sullivan, S.E. (2017a). A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight, 2(12).
46. Rajesh, M., Mukhopadhyay, P., Bátkai, S., Patel, V., Saito, K., Matsumoto, S., Kashiwaya, Y., Horváth, B., Mukhopadhyay, B., Becker, L., Haskó, G., Liaudet, L., Wink, D.A., Veves, A., Mechoulam, R. and Pacher, P. (2010). Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory, and cell death signaling pathways in diabetic cardiomyopathy. Journal of the American College of Cardiology, [online] 56(25), pp.2115–2125.
47. Bidwell, L.C., Mueller, R., YorkWilliams, S.L., Hagerty, S., Bryan, A.D., and Hutchison, K.E. (2018). A Novel Observational Method for Assessing Acute Responses to Cannabis: Preliminary Validation Using Legal Market Strains. Cannabis and Cannabinoid Research, [online] 3(1), pp.35–44.
48. Government of Canada, Statistics Canada (2015). Experimental Estimates of Cannabis Consumption in Canada, 1960 to 2015. [online] Statcan.gc.ca.
49. Kogan, N.M., and Mechoulam, R. (2007). Cannabinoids in health and disease. Dialogues in clinical neuroscience, [online] 9(4), pp.413–30.
50. Durst, R., Danenberg, H., Gallily, R., Mechoulam, R., Meir, K., Grad, E., Beeri, R., Pugatsch, T., Tarsish, E. and Lotan, C. (2007). Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. American Journal of Physiology-Heart and Circulatory Physiology, 293(6), pp.H3602–H3607.
51. NCBI (2016). The Basics of Bone in Health and Disease. Nih.gov.
52. www.royalqueenseeds.com. (n.d.). Research Finds How Cannabis Supports Bone Health – RQS Blog.
53. Jadoon, K.A., Ratcliffe, S.H., Barrett, D.A., Thomas, E.L., Stott, C., Bell, J.D., O’Sullivan, S.E., and Tan, G.D. (2016). Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study. Diabetes Care, 39(10), pp.1777–1786.
54, 55. Lehmann, C., Fisher, N.B., Tugwell, B., Szczesniak, A., Kelly, M., and Zhou, J. (2016a). Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Clinical Hemorheology and Microcirculation, 64(4), pp.655–662.
56. Le Strat, Y. and Le Foll, B. (2011). Obesity and cannabis use: results from 2 representative national surveys. American Journal of Epidemiology, 174(8), pp.929–933.
57. Weiss, L., Zeira, M., Reich, S., Har-Noy, M., Mechoulam, R., Slavin, S., and Gallily, R. (2006). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity, 39(2), pp.143–151.
58. Conscious Lifestyle Magazine. (2017). The Keys to Brain Health: 10 Supplements and Habits That Supercharge Your Brain.
59, 60. Maroon, J., and Bost, J. (2018a). Review of the neurological benefits of phytocannabinoids. Surgical Neurology International, 9(1), p.91.
61. Perucca, E. (2017a). Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? Journal of Epilepsy Research, 7(2), pp.61–76.
62. Libro, R., Diomede, F., Scionti, D., Piattelli, A., Grassi, G., Pollastro, F., Bramanti, P., Mazzon, E., and Trubiani, O. (2016). Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells. International Journal of Molecular Sciences, 18(1).
63. Rahn, E.J., and Hohmann, A.G. (2009). Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics, 6(4), pp.713–737.
64. Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S.-R., Willenbring, D., Guan, Y., Pan, H.-L., Ren, K., Xu, Y. and Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. The Journal of Experimental Medicine, 209(6), pp.1121–1134.\\
65. Welty, T.E., Luebke, A., and Gidal, B.E. (2014). Cannabidiol: Promise and Pitfalls. Epilepsy Currents, 14(5), pp.250–252.
66. Ibeas Bih, C., Chen, T., Nunn, A.V.W., Bazelot, M., Dallas, M. and Whalley, B.J. (2015). Molecular Targets of Cannabidiol in Neurological Disorders. Neurotherapeutics, 12(4), pp.699–730.
67. Zanelati, T., Biojone, C., Moreira, F., Guimarães, F., and Joca, S. (2009). Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. British Journal of Pharmacology, 159(1), pp.122–128.
68. Lee, J.L.C., Bertoglio, L.J., Guimarães, F.S., and Stevenson, C.W. (2017). Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. British Journal of Pharmacology, 174(19), pp.3242–3256.
69. Jurkus, R., Day, H.L.L., Guimarães, F.S., Lee, J.L.C., Bertoglio, L.J., and Stevenson, C.W. (2016). Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders. Frontiers in Pharmacology, 7.
70. Blessing, E.M., Steenkamp, M.M., Manzanares, J., and Marmar, C.R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics, 12(4), pp.825–836.\
71. Shannon, S. (2019). Cannabidiol in Anxiety and Sleep: A Large Case Series. The Permanente Journal.
72. Prud’homme, M., Cata, R. and Jutras-Aswad, D. (2015). Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence. Substance Abuse: Research and Treatment, 9, p.SART.S25081.
73, 74 Morgan, C.J.A., Das, R.K., Joye, A., Curran, H.V., and Kamboj, S.K. (2013). Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addictive behaviors, 38(9), pp.2433–6.
75. Psychiatryonline.org. (2010). American Journal of Psychiatry.
76. ScienceDaily. (n.d.). Neurobiologist illuminates the underexplored potential of cannabis to address opioid addiction.
77. Stampanoni Bassi, M., Gilio, L., Maffei, P., Dolcetti, E., Bruno, A., Buttari, F., Centonze, D., and Iezzi, E. (2018). Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression. Frontiers in Molecular Neuroscience, 11, p.424.
78. Oláh, A., Tóth, B.I., Borbíró, I., Sugawara, K., Szöllõsi, A.G., Czifra, G., Pál, B., Ambrus, L., Kloepper, J., Camera, E., Ludovici, M., Picardo, M., Voets, T., Zouboulis, C.C., Paus, R. and Bíró, T. (2014). Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. The Journal of Clinical Investigation, 124(9), pp.3713–3724.
79. Niesink, R.J.M., and van Laar, M.W. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC? Frontiers in Psychiatry, 4.
80. Blake, D.R., Robson, P., Ho, M., Jubb, R.W., and McCabe, C.S. (2005). Preliminary assessment of the efficacy, tolerability, and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumat
ology, 45(1), pp.50–52.
81. Russo, M., Calabrò, R.S., Naro, A., Sessa, E., Rifici, C., D’Aleo, G., Leo, A., De Luca, R., Quartarone, A. and Bramanti, P. (2015). Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plasticity, 2015, p.656582.
82. Watt, G., and Karl, T. (2017). In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease. Frontiers in Pharmacology, 8.
83. Aso, E., and Ferrer, I. (2014). Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. Frontiers in pharmacology, 5, p.37.
84. Iffland, K., and Grotenhermen, F. (2017). An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis and Cannabinoid Research, 2(1), pp.139–154.
85. Fakhoury, M. (2016). Could cannabidiol be used as an alternative to antipsychotics? Journal of Psychiatric Research, 80, pp.14–21
86. Gage, S.H., Hickman, M., and Zammit, S. (2016). Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biological Psychiatry, 79(7), pp.549–556.
87. Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., and Mazzon, E. (2019). Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. Molecules, 24(8), p.1459.
88, 89. Perucca, E. (2017b). Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last? Journal of Epilepsy Research, 7(2), pp.61–76.
90. Elms, L., Shannon, S., Hughes, S., and Lewis, N. (2019). Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. The Journal of Alternative and Complementary Medicine, 25(4), pp.392–397.
91. Fraser, G.A. (2009). The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS neuroscience & therapeutics, 15(1), pp.84–8.
92. Bitencourt, R.M., and Takahashi, R.N. (2018). Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials. Frontiers in Neuroscience, 12.
93. Quintana, M. (2019). CBD Oil Benefits | The Best CBD Oil Digestive Aid. INQUIRER.net USA.
94. Ahmed, W., and Katz, S. (2016b). Therapeutic Use of Cannabis in Inflammatory Bowel Disease. Gastroenterology & hepatology, 12(11), pp.668–679.
95. Nagarkatti, P., Pandey, R., Rieder, S.A., Hegde, V.L., and Nagarkatti, M. (2009). Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 1(7), pp.1333–1349.
96. Malfitano, A.M., Basu, S., Maresz, K., Bifulco, M. and Dittel, B.N. (2014). What We Know and Don’t Know About the Cannabinoid Receptor 2 (CB2). Seminars in immunology, 26(5), pp.369–379.
97. Eisenstein, T.K., and Meissler, J.J. (2015a). Effects of Cannabinoids on T-cell Function and Resistance to Infection. Journal of Neuroimmune Pharmacology, 10(2), pp.204–216.
Clinical trials  showed that CBD significantly reduces or ceases flashbacks, persistent unpleasant memories  , and nightmares in PTSD patients. Hence, CBD can effectively attenuate significant symptoms of PTSD like reducing anxiety, consolidating fear of memories, and improve sleep.